New hope for advanced lung cancer: drug combo enters phase 2 trial
NCT ID NCT07253142
First seen Jan 10, 2026 · Last updated May 15, 2026 · Updated 20 times
Summary
This study tests a new combination of two drugs, HLX43 and serplulimab, in 120 people with advanced lung cancer that has spread or cannot be removed by surgery. The goal is to find the best dose and see if the treatment can shrink tumors. Participants must be between 18 and 75 years old and have a confirmed diagnosis of non-small cell or small cell lung cancer without certain genetic changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.